Clinical outcome of management of acute myeloid leukemia with idarubicin plus cytarabine


  • Muhammad Hafeez
  • Shaharyar ,
  • Khalid Shabbir
  • Zafar Alauddin
  • Muhammad Farooq
  • Muhammad farooq



Idarubicin. Cytarabine. Leukemia, Myeloid, Acute. Prospective Study. Leukemia, Myeloid. Trisomy. Leukemia. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Chromosomes, Human, Pair 18.


A prospective study was conducted at Department of Clinical Oncology, King Edward Medical College / Mayo Hospital, Lahore from July 2003 to June 2004 to evaluate the effect of Idarubicin plus Cytarabine in chemo naive Acute Myeloid Leukemia (AML) patients. A total of 15 consecutive patients were enrolled with age group 15-58 years. Patients were classified according to French American British (FAB) classification. Induction therapy with Cytarabine as continuous infusion for 7 days and Idarubicin was given on day 1-3. For assessment of response, all patients were subjected to bone marrow examination fifteen days after completion of Induction chemotherapy. Consolidation Therapy with high dose Cytarabine was given on days 1, 3 and 5. Cytarabine was repeated after 28 days for 4 cycles in patients with complete remission after induction therapy. A remission induction rate of 66.7% was observed. Four patients died because of complications. One patient lost to follow up. Idarubicine and cytarabine is effective r egimen for achieving complete remission in AML Chemo-naive patients.



How to Cite

Hafeez, M., , S., Shabbir, K., Alauddin, Z., Farooq, M., & farooq, M. (2016). Clinical outcome of management of acute myeloid leukemia with idarubicin plus cytarabine. Annals of King Edward Medical University, 11(4).




Most read articles by the same author(s)

> >>